Frontlight ResearchEarly access
Taking people in ItalyPhase 2
Imaging scan tested for finding clinically relevant prostate cancer
Tests a PSMA PET/MRI scan in adults suspected of having prostate cancer.
Key facts
- Who runs it
- Ospedale San Raffaele S.r.l.
- Where
- Milan, ItalySee the site
- Registry title
- Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 167 people, planned
- Started
- 4 Dec 2023
- Expected to end
- 28 Apr 2027
- Type of study
- Interventional
- Record updated
- 8 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 18 or older who are suspected of having prostate cancer that matters clinically. It tests how well a 18F-PSMA PET/MRI scan finds this cancer.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Suspected clinically significant prostate cancer, not yet diagnosed
Main reasons for not taking part
- Already diagnosed with prostate cancer
- Cannot have an MRI scan (for example claustrophobia, pacemaker, estimated GFR of 50 mls/min or less)
- Cannot have a prostate biopsy
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients 18 years of age or older, identified as suspects for clinically significant prostate cancer
- Ability to undergo all protocol scrutiny
- Ability to provide informed consent
Who cannot take part
- Previous diagnosis of prostate cancer
- Contraindications to perform the MRI examination (e.g. claustrophobia, pacemaker, estimated GFR less than or equal to 50mls/min)
- Contraindications to perform the prostate biopsy
Where in Italy
- Ospedale San Raffaele S.r.l.Milan, ItalyTaking people
About the trial
What the trial wants to find out
To determine the diagnostic accuracy of 18F-PSMA PET/MRI for the diagnosis of clinically relevant prostate cancer
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer
- Plain-language title
- Imaging scan tested for finding clinically relevant prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 8 September 2026